Atea Pharmaceuticals Inc (AVIR) Stock Price, Quote & News

Latest News on AVIR

Mar 31, 2025, 7:04 PM EDT - 2 days ago

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination

Mar 26, 2025, 1:58 PM EDT - 7 days ago

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Mar 26, 2025, 8:00 AM EDT - 7 days ago

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Mar 21, 2025, 5:54 PM EDT - 12 days ago

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Mar 19, 2025, 7:00 AM EDT - 14 days ago

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Mar 6, 2025, 6:14 PM EST - 27 days ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:05 PM EST - 27 days ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 4 weeks ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Feb 24, 2025, 7:00 AM EST - 5 weeks ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Jan 8, 2025, 7:00 AM EST - 3 months ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 5:05 PM EST - 3 months ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Dec 16, 2024, 5:00 AM EST - 3 months ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Dec 4, 2024, 3:14 PM EST - 4 months ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Dec 4, 2024, 7:00 AM EST - 4 months ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Nov 26, 2024, 7:00 AM EST - 4 months ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Nov 15, 2024, 11:00 AM EST - 4 months ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Nov 9, 2024, 1:14 PM EST - 5 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 5 months ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 7:00 AM EDT - 5 months ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Sep 13, 2024, 7:00 AM EDT - 7 months ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Aug 28, 2024, 7:00 AM EDT - 7 months ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Aug 11, 2024, 12:13 PM EDT - 8 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 8 months ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

May 29, 2024, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 22, 2024, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

May 14, 2024, 10:00 PM EDT - 11 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Mar 27, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Feb 28, 2024, 11:24 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 21, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Jan 8, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Jan 3, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Nov 8, 2023, 6:51 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 1, 2023, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

May 30, 2023, 7:00 AM EDT - 2 years ago

Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

May 23, 2023, 4:05 PM EDT - 2 years ago

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

May 8, 2023, 8:51 PM EDT - 2 years ago

Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript

May 8, 2023, 4:05 PM EDT - 2 years ago

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 4:05 PM EDT - 2 years ago

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

Apr 25, 2023, 7:00 AM EDT - 2 years ago

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

Apr 12, 2023, 7:00 AM EDT - 2 years ago

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

Mar 14, 2023, 7:00 AM EDT - 2 years ago

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Mar 8, 2023, 7:00 AM EST - 2 years ago

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

Market Cap	255.72M
Revenue (ttm)	0.00
Net Income (ttm)	-168.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	245,100
Avg Vol	310,992
Day's Range	N/A - N/A
Shares Out	85.53M
Stochastic %K	21%
Beta	0.18
Analysts	Hold
Price Target	$6.20